Compare Cytokinetics Inc (CYTK) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Cytokinetics Inc trades at $62.9 (market cap $8.62B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $214.13 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 4.5× Cytokinetics Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is more actively traded (2,708,429 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 110 Days on average.
| CYTK | TTWO | |
|---|---|---|
Market Cap | $8.62B | $39.15B |
Volume | 2,594,626 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $87.26 | $262.29 |
52-Week Low | $54.76 | $189.69 |
Typical Hold Time | 19 Days | 110 Days |
Enterprise Value | $8.72B | $40.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Take-Two Interactive trades at $204.01, up 0.73% with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $5.63B but faces profitability challenges with a -79.51% net margin. Analyst consensus remains strongly bullish with a $292.30 price target, supported by GTA VI's confirmed November 2026 launch. Cash flow improved significantly to $457M in 2025, though debt-to-asset ratio rose to 39.87%.
The stock presents a high-risk, high-reward opportunity with GTA VI as the primary catalyst. While current fundamentals show losses, the 79% buy rating reflects optimism for the upcoming release. Key risks include execution on the major title launch, competitive pressure, and the company's elevated debt levels. Near-term performance will likely hinge on pre-launch momentum and Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
